The term bispecific antibody (bsAb) is used to describe a large family of molecules designed
to recognize two different epitopes or antigens. BsAbs come in many formats, ranging from …

Bispecific molecules redirecting the cytotoxicity of T-cells are a growing class of therapeutics
with numerous molecules being tested in clinical trials. However, it has been a long way …

The concepts for T-cell redirecting bispecific antibodies (TRBAs) and chimeric antigen
receptor (CAR)-T cells are both at least 30 years old but both platforms are just now coming …

ABSTRACT T-cell-recruiting bispecific antibodies (T-BsAbs) have shown potent tumor killing
activity in humans, but cytokine release-related toxicities have affected their clinical utility …

Human CLDN18. 2 is highly expressed in a significant proportion of gastric and pancreatic
adenocarcinomas, while normal tissue expression is limited to the epithelium of the …

Cancer immunotherapy is a highly active area in translational medicine where the
challenges and rewards of developing new drugs “from bench to bedside” become …

Cancer immunotherapy involves the delivery of immunogenic compounds and/or the
priming, or induction, of the body's natural immune system to target cancer. The use of …

Although CD3 T cell redirecting antibodies have been successfully utilized for the treatment
of hematological malignancies (blinatumomab), the T cell signaling pathways induced by …

This chapter discusses the background work to the development of unconjugated antibodies
for potential therapeutic uses in vivo. The immunoglobulin molecules and their associated …

This invention relates to agents that are inhibitors or acti vators of variant forms of
endogenous proteins and novel methods of identifying such variants. Of particular interest …